Dr. Eric Ruderman gives his perspective on PsA data presented during the plenary session on Saturday at the #ACR21 annual meeting. https://t.co/r9FgBO6VT7 https://t.co/JbV519XQoG

• https://bit.ly/3kcOt0c

Important differences between vascular pathologies seen in #COVID19 and DIC by Dr. D McGonagle 👉Fibrinogen - normal/sl. ⬆ in PIC-assoc'd COVID19 vs. ⬇ in DIC sec to MAS @RheumNow #ACR21 #MedTwitter 📌https://t.co/DdmAhVIR51 https://t.co/Xw8LKaKcFd

• DEFINE_ME

Dr. D.McGonagle on the patterns of dse ➡true #vasculitis vs. vasculitis mimics seen in skin of #COVID19 pts in this very informative slide 🔴Mild/no lung dse: vasc cuffing,⬆type1 IFN 🔴Severe dse: vasc occlusion,⬇type1 IFN @RheumNow #ACR21 #MedTwitter https://t.co/Y5S2k7LO1p https://t.co/puBJm4Kd8H

• DEFINE_ME

Interesting twist to an #ACR21 keynote lecture: Q&A!👏👏@DoctorYasmin She even eloquently explained the etymology of crisis-the point in a pt's illness where they might rapidly deteriorate or recover, an inflection point (so relevant now) 👉to a new BETTER normal @RheumNow https://t.co/UMKIC1tNos

#ACR21 #YearinReview Avacopan: The game changer for ANCA #vasculitis?🧐 🔅Remission at wk 26: Avacopan non-inferior to Pred (72.3% vs. 70.1%, p<0.001) 🔅Sustained remission at wk 56: Avacopan non-inferior to Pred (65.7% vs. 54.9%, p<0.001) @RheumNow https://t.co/CpPYVvRoMR https://t.co/QnsZIUQ0uu

• https://bit.ly/2ZNHhAi

The AURORA 1 trial provided positive results for #lupus nephritis 👉rapid control of proteinuria w/o major side effects. @RheumNow #ACR21 #YearinReview https://t.co/BWWZJtMPK0

To cut back or continue? 🤔 The ARCTIC REWIND trial showed that RA pts in remission given half dose csDMARDs had ⬆ flares in 12 mos vs. stable dose csDMARD grp. @RheumNow #ACR21 #YearinReview https://t.co/MXyD0epVcn

Excited for the first full day of #ACR21, reporting for @RheumNow! Esp looking forward to: ⭐Posters: #Epidemiology, #PublicHealth, #COVID19, #SpA, #RheumatoidArthritis, #PatientOutcomes ⭐Plenary session ⭐Scientific sessions covering #axSpA, #PsA and more

Some great #SpA posters on #WorkParticipation #ACR21 Abs#0358 •~700 pts •379 (64.2%) took sick leave in last 12m •#Absenteeism in 23.7% & #presenteeism in 84.1% •Huge impact on work participation in SpA despite incr no. of therapeutic agents @RheumNow https://t.co/pwz4s8D1FU https://t.co/wpbjeXNpgm

• Work Participation in Patients with Axial Spondyloarthritis in Germany: Results…

#ACR21 1st/2 abstracts by @ElenaNikiUK on #work & #sickleave in #SpA Abs#0380 •~700pts •Old age & high disease activity👉🏼 ⬆️risk of sick leave •Must address #socioeconomic factors w/ disease activity to improve work outcomes in #SpA @RheumNow #ACRBest https://t.co/uixuGGEFJG https://t.co/WZoqWLaY1Q

• Sick Leave and Its Predictors in Early Axial Spondyloarthritis: The Role of Cli…

#ACR21 2nd abstract #0381 from #DESIR cohort by @ElenaNikiUK: •High disease activity & decreased function assoc w/ greater #WorkDisability •Not enough to just treat the disease! Need holistic approaches to improve function, QoL & work outcomes. @RheumNow https://t.co/jIs3Oj7nbJ

• How Do Clinical and Socioeconomic Factors Impact on Work Disability in Early Ax…

#ACR21 Abs#0101 on recombinant #zoster vaccine (RZV) in #IMIDs: •High proportion of ≥50yos w/ IMIDs received RZV but 15–25% did not get 2nd dose within 6m •#Vaccination higher in ≥65yos than 50–64yos •Need better vaccine policy to encourage uptake in pts w/ IMIDs @RheumNow https://t.co/i5JDJClTyQ

Freq & severity of adverse events after #SARSCoV2 #vaccine in patients with autoimmune disease vs controls Abs#0104 #ACR21 •No incr. risk of AEs in autoimmune disease vs controls •Minimal impact of vaccines on disease activity @RheumNow https://t.co/jGXP5UL4LP https://t.co/980NLWQYeX

• Adverse Events of First SARS-CoV-2 Vaccinations Are Comparable for Patients wit…

Well done 👏@DrCMcMaster @victor_yang1 on this great work - using machine learning to pick apart GCA from its mimics. Predicting mimics improves prediction, especially in the quagmire of biopsy-negative GCA (also excellent memes in this Twitter thread) #ACR21 ABST1417 @RheumNow https://t.co/cS3fMLwem4

• Christopher McMaster on Twitter: &quot;We put all of this into a random forest …

@RheumNow Janet Zeide @Wharton - if the purpose = persuade: e.g. persuading an audience, persuading pts to change - ethos/logos/pathos - remove barriers to action (cost of not changing, incremental change) - state & refute counter-arguments - know & engage your audience #ACR21 @RheumNow https://t.co/JU2WeNYDvz